GUILLERMO GARCIA-MANERO to Chromosome Deletion
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Chromosome Deletion.
Connection Strength
0.990
-
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009 Nov 15; 115(22):5202-9.
Score: 0.255
-
Chromosomal abnormalities in chronic lymphocytic leukemia. N Engl J Med. 2001 Apr 19; 344(16):1254.
Score: 0.141
-
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leuk Lymphoma. 2018 09; 59(9):2135-2143.
Score: 0.112
-
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol. 2016 Apr; 173(1):161-5.
Score: 0.094
-
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol. 2012 Apr 30; 5:18.
Score: 0.076
-
Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk Res. 2011 Mar; 35(3):351-7.
Score: 0.067
-
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. 2009 Sep; 23(9):1605-13.
Score: 0.061
-
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005 Mar 15; 105(6):2281-6.
Score: 0.045
-
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma. 2022 12; 63(13):3105-3116.
Score: 0.039
-
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071.
Score: 0.036
-
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. Medicine (Baltimore). 2019 Jan; 98(1):e14011.
Score: 0.030
-
Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leuk Res. 2011 Jun; 35(6):834-6.
Score: 0.017
-
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011 Jan; 25(1):110-20.
Score: 0.017